Large-Scale Meta-Analysis Finds No Significant Vision Risk from GLP-1 Receptor Agonists in 80,000+ Patients
核心洞察
A comprehensive meta-analysis of over 80,000 patients with diabetes (搜索) and heart disease (搜索) found no significant association between GLP-1 receptor (搜索) agonist use and ischaemic optic neuropathy (搜索) risk.
The study represents the largest sample size examined to date for evaluating vision-threatening complications associated with this emerging cardiometabolic drug class.
Additional research demonstrated that every 1% weight reduction in obese atrial fibrillation (搜索) patients was associated with a 6.3% reduction in relative risk of AF recurrence after catheter ablation.
A research team from the University of Hong Kong's Faculty of Medicine has conducted the largest meta-analysis to date examining the safety profile of GLP-1 receptor agonists, analyzing data from more than 80,000 patients with diabetes (搜索) and heart disease (搜索). The comprehensive study found no significant association between GLP-1 receptor (搜索) agonist use and the risk of ischaemic optic neuropathy (搜索), addressing growing concerns about potential vision-threatening complications from this emerging cardiometabolic drug class.
Addressing Safety Concerns in Expanding Clinical Use
GLP-1 receptor agonists have emerged as an important therapeutic class for treating obesity (搜索), diabetes (搜索), and cardiometabolic diseases. However, as their clinical use continues to expand, concerns about potential side effects have grown. Previous research had indicated a possible link between GLP-1 receptor agonists and ischaemic optic neuropathy (搜索), a serious ocular complication that can cause sudden, painless vision loss and visual field defects, particularly among individuals with diabetes and hypertension (搜索).
The evidence regarding this risk had remained inconsistent and conflicting, prompting the HKUMed (搜索) team to conduct their comprehensive meta-analysis. The study represents the largest sample size examined in this field to date, providing clearer evidence for formulating clinical treatment plans and enabling doctors to comprehensively assess the benefits and risks of these medications.
Weight Management Enhances Cardiac Intervention Success
In parallel research, the team analyzed data from 5,415 patients with atrial fibrillation (搜索) and discovered significant benefits of weight management for surgical outcomes. The study found that for individuals with obesity (搜索), every 1% reduction in weight was associated with a 6.3% reduction in the relative risk of AF recurrence after catheter ablation.
Atrial fibrillation (搜索) represents the most common cardiac arrhythmia encountered in clinical practice and can result in life-threatening complications, including stroke (搜索) and heart failure (搜索). The findings highlight that sustained weight control is a critical factor in operative success, suggesting that cardiac patients with obesity (搜索) may improve the long-term success rate of catheter ablation for atrial fibrillation through a holistic approach to weight control.
Comprehensive Treatment Approach Recommended
The research indicates that optimal treatment outcomes require patients to adopt a comprehensive cardiovascular risk management strategy, incorporating healthier lifestyle choices and various clinical interventions, including GLP-1 receptor agonists, rather than relying solely on medication. This integrated approach to weight management and medication represents a significant advancement in treating cardiac patients with obesity (搜索).
Clinical Implications and Expert Perspective
Lead investigator Dr. Will Chan Yap-hang, Clinical Assistant Professor in the Department of Medicine at HKUMed (搜索), emphasized the clinical significance of the findings. "Our meta-analysis of clinical trial data provides important evidence regarding both the safety profile and novel use of GLP-1 receptor agonists in cardiovascular patients. This will help doctors more comprehensively evaluate the potential risks and benefits of prescribing these medications," Dr. Chan stated.
However, he cautioned that the research does not completely rule out the possibility of rare adverse complications. "Clinicians must exercise careful judgement based on each patient's condition. It is essential not to overemphasise the potential benefits while overlooking the associated risks, and to always assess the situation holistically," he added.
The findings were published in Diabetes (搜索) Care, the journal of the American Diabetes Association, and were presented at the European Heart Rhythm Association Congress in Vienna in 2025. The interdisciplinary study was co-led by Dr. Will Chan Yap-hang and Professor Tse Hung-fat, Chair Professor and Department Chairperson, with Ms. Kathleen Li Hoi-ying as first author.